Seres Therapeutics receives award of up to $3.6M from CARB-X

Seres Therapeutics (MCRB) will provide up to $3.6 million in additional non-dilutive funding to the Company. The grant will support development and manufacturing of an oral liquid formulation of Seres’ Breakthrough Therapy designated SER-155, for medically vulnerable patient populations at risk of bloodstream infections, including antimicrobial resistant infections, who cannot be dosed with oral capsules, such as intubated patients in the ICU.